期刊文献+

利拉鲁肽对ApoE基因缺陷小鼠动脉粥样硬化及相关危险因素的影响 被引量:3

Effects of glucagon like peptide- 1 analogue, liraglutide, on atherosclerosis in ApoE deficient mice
原文传递
导出
摘要 目的观察长效胰高糖素样肽-1类似物利拉鲁肽对Apo E基因缺陷小鼠动脉粥样硬化及相关血清学指标的影响。方法高脂饲料喂养Apo E基因缺陷小鼠诱导动脉粥样硬化形成,并随机分为对照组(不给药,n=11)和利拉鲁肽组(30μg·d-1,皮下注射,共4周,n=12)。比较两组小鼠主动脉粥样硬化斑块面积/管腔面积、内膜厚度/中膜厚度、血脂、血清一氧化氮(NO)、肿瘤坏死因子α(TNF-α)、丙二醛(MDA)水平。结果对照组和利拉鲁肽组小鼠斑块面积/管腔面积、内膜厚度/中膜厚度无显著差异(P>0.05),两组中体重增加在中位数以下的小鼠进行亚组比较,利拉鲁肽组斑块面积/管腔面积、内膜厚度/中膜厚度均显著下降(P<0.05)。利拉鲁肽组总胆固醇、三酰甘油、低密度脂蛋白胆固醇、TNF-α水平显著低于对照组(P<0.05),NO水平显著高于对照组(P<0.05),两组间MDA水平无显著差异(P>0.05)。结论利拉鲁肽具有减轻体重、改善血脂水平,保护内皮功能及抑制炎症反应等作用,并可能通过减轻体重发挥潜在的抗动脉粥样硬化作用。 AIM To investigate the effects of long active glucagon-like peptide- 1 analogue, liraglutide, on atherosclerosis and related serum indicators in ApoE deficient mice. METHODS ApoE deficient mice, fed with high-fat-diet to establish atherosclerotic model, were randomly divided into control group (noadminstration, n ~ 11) and liraglutide group (30 jxg per day, injected subcutaneously for 4 weeks, n = 12). The aorta was separated and the area ratio of plaque and lumen, the thickness ratio of endangium and tunica media were analyzed. The levels of serum lipid, NO, tumor necrosis , factor- α (TNF- α), malondialdehyde (MDA) were also measured. RESULTS There were no significant difference between the two groups in the area ratio of plaque and lumen, the thickness ratio of endangium and tunica media (P 〉 0.05). But when compared in the mice with body weight increase blow the median of the two groups (P 〈 0.05) , the above ratios were significant decreased in the liraglutide group (P 〈 0.05). The levels of serum TC, LG, LDL-C, NO, TNF-α of liraglutide group were significant lower than the control group (P 〈 0.05). There was no difference between two groups in MDA levels (P 〉 0.05). CONCLUSION Liraglutide may be able to reduce weight, improve lipid metabolism, protect endothelial function and inhibit inflammation in ApoE deficient mice. Through reducing weight, liraglutide may inhibit atherosclerosis progress.
出处 《中国新药与临床杂志》 CSCD 北大核心 2015年第6期455-459,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 辽宁省博士启动基金资助项目(20121114)
关键词 利拉鲁肽 载脂蛋白E类 小鼠 基因敲除 动脉粥样硬化 liraglutide apolipoproteins E mouse, knockout atherosclerosis
  • 相关文献

参考文献2

二级参考文献44

  • 1WOLF PA, D'AGOSTINO RB, BELANGER AJ, et al. Probability of stroke: a risk profile form the Framingham study[J]. Stroke, 1991, 22(3): 312-318.
  • 2The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy[J]. Ann Intern Med, 1995, 122 (8) : 561-568.
  • 3The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus [ J]. Arch Ophthalmol, 1995, 113 ( 1 ) : 36-51.
  • 4The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long- term complications : the perspective of the Diabetes Control and Complications Trial[J]. Diabetes, 1996, 45(10): 1289-1298.
  • 5The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the developement and progression of long-term complications in insulin dependent diabetes mellitus[J]. N Engl J Med, 1993, 329(14): 977-986.
  • 6The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial[J]. Kidney Int, 1995, 47(6) : 1703-1720.
  • 7The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial[J]. Diabetes, 1997, 46(2): 271-286.
  • 8PALMER A J, ROZE S, VALENTINE WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies[J]. Curr Med Res Opin, 2004, 20 Suppl 1 : 27-40.
  • 9SULLIVAN SD, ALFONSO-CRISTANCHO R, CONNER C, et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone[J]. Cardiovasc Diabetol, 2009, 8: 12-20.
  • 10PRATLEY RE, NAUCK M, BAILEY T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with mefformin: 26-week, radomised, parallel-group, open-label triM[J]. Lancet, 2010, 375 (9724): 1447-1456.

共引文献19

同被引文献91

  • 1卜军,陈章炜,崔晓通,范凡,高平进,高鑫,高秀芳,葛均波,何奔,胡凯,姜林娣,李小英,李燕,李毅刚,李勇,梁春,刘学波,刘宗军,彭永德,钱菊英,沈成兴,盛长生,孙爱军,王大英,王继光,谢坤,徐磊,闫小响,张瑞岩,赵仙先,周京敏,邹云增.中国成人代谢异常与心血管疾病防治[J].上海医学,2020(3):129-164. 被引量:47
  • 2朱旅云,刘月红,王广宇,胡丽叶,单巍.肥胖者内皮功能障碍与胰岛素抵抗关系的研究[J].解放军医学杂志,2006,31(1):71-73. 被引量:14
  • 3Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2003, 26 Suppl 1: $5-$20.
  • 4DAVIGNON J, GANZ P. Role of endothelial dysfunction in atherosclerosis [J]. Circulation, 2004, 109 (23 Suppl 1): Ill 27- m 32.
  • 5MADAMANCHI NR, VENDROV A, RUNGE MS. Oxidative stress and vascular disease[J]. Arterioseler Thromb Vase Biol, 2005, 25 ( 1 ) : 29-38.
  • 6SHIRAKI A, OYAMA J, KOMODA H, et al, The glueagon-like peptide 1 analog liraglutide reduces TNF- c- induced oxidative stress and inflammation in endothelial cells[J]. Atheroselerosis, 2012, 221(2): 375-382.
  • 7ERDOGDU 0, ERIKSSON L, NYSTROM T, et td. Exendin-4 restores glucolipotoxieity- induced gcne expression in human coronary artery endothelial eell[J]. Biochem Biophys Res Commun, 2012, 419(4): 790-795.
  • 8OESEBURG H, de BOER RA, BUIKEMA H, et cd. Glueagon- like peptide 1 prevents reactive oxygen species- induced endothelial cell senescence through the activation of protein kinase A[J]. Arterioseler Thromb Vase Biol, 2010, 30(7): 1407- 1414.
  • 9VILSBOLL T, ZDRAVKOVIC M, LE-THI T, et ol. Liraglutide, a long acting human glueagon - like peptide - l analo, given as monotherapy significantly improves glyeemie control and lowe body weight without risk of hypoglycemia in patients with type 2 diabetes[J]. Diabetes Care, 2007, 30(6) : 1608-1610.
  • 10BURGMAIER M, HEINRICH C, MARX N. Cardiovascular effects of GLP- 1 and GLP- 1 - based therapies: implications for the cardiovascular continuum in diabetes?[J]. Diabet Med, 2012, 30 (3) : 289-299.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部